DAT-Schaub enters the US pharmaceutical market with a new acquisition
DAT-Schaub has been selling mucosa and crude heparin, which is extracted for anticoagulant drugs from the mucous membranes of pig intestines, in Europe for decades.
The company's activities are now being developed further to include a plant in the town of Oelwein in the state of Iowa.
"This is an attractive market for several reasons. Around 120 million pigs are slaughtered in the US every year, and the potential for extracting mucosa is therefore huge. At the same time, we see a stable demand for crude heparin from the global pharmaceuticals industry, which makes this a sound business venture," says Jan Roelsgaard, CEO of DAT-Schaub.
The company also announced that it has access to large quantities of raw materials through its US company DCW, the acquisition being a good strategic match.
According to Danish Crown’s 4WD strategy, DAT-Schaub is set to become a a global market leader in the handling and processing of natural casings before the end of 2021.
Starting with 2017, DAT-Schaub has established new activities in Spain, South America and China. Now, the US being next in line.
Mr Coudry-Mesny, who graduated from ESIAE Business School, holds a Master’s in Food Marketi...
Friland ensures progress and increases revenue in the first half of 2025/26, which has otherwise ...
The National Feedlot Survey has confirmed a new record turn-off from Australian feedlots of over ...
